Front Page-Rx

Comparison of State Pharmacy Benefit Managers Laws

In 2018, 21 states passed 32 bills to shed light on the opaque business practices of pharmacy benefit managers (PBMs). States took varied approaches to curb prescription drug costs by regulating PBMs. The chart below details the PBM practices each state tackled, and how their approaches compare with NASHP’s PBM model legislation.   Footnotes 1. Bills […]

Read More
  • NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database

    NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database

    NASHP’s Center for State Rx Drug Pricing seeks a partner to provide technical and strategic expertise to help a workgroup of state officials from California, Nevada, Oregon, Connecticut, and Vermont implement their drug cost transparency laws and help Maine and New Hampshire develop transparency programs as mandated by recent legislation. This work will help all […]

    Read More
    September 18, 2018 | Filed under: Drug Pricing, Featured-Rx, Front Page, Front Page-Rx, Transparency

  • State Health Policy Blog
    As States Take the Lead to Address Drug Costs, Federal Action Follows

    As States Take the Lead to Address Drug Costs, Federal Action Follows

    *Update: On Oct. 10, 2018, President Trump signed two bills designed to increase prescription drug price transparency by prohibiting gag clauses, which prevent pharmacists from disclosing lower-cost drug options to consumers. One bill prohibits gag clauses under Medicare Part D starting in 2020 and the other affects private insurance markets and goes into effect immediately. […]

    Read More
  • State Health Policy Blog
    New NASHP Model Legislation Helps States Bring Transparency to Pharmacy Benefit Managers

    New NASHP Model Legislation Helps States Bring Transparency to Pharmacy Benefit Managers

    The National Academy for State Health Policy (NASHP) has released model legislation to help states shed light on the opaque business practices of pharmacy benefit managers (PBMs). States can use the model bill to require the licensing of PBMs, ban gag clauses that prevent pharmacists from sharing lower-price drug options with consumers, and require more […]

    Read More
  • State Health Policy Blog
    State Lawmaker Will Guzzardi Plots His Next Move to Curb Generic Drug Price Gouging in Illinois

    State Lawmaker Will Guzzardi Plots His Next Move to Curb Generic Drug Price Gouging in Illinois

    Earlier this year, Illinois state Rep. Will Guzzardi proposed an aggressive, anti-price-gouging bill that banned manufacturers from excessively hiking the costs of generic drugs sold to Illinois residents for his first foray into prescription cost control legislation. Guzzardi’s bill was one of a dozen anti-price gouging measures introduced in state legislature this year. The bill […]

    Read More
  • Pharmacy Benefit Manager Model Legislation: Questions and Answers

    Pharmacy Benefit Manager Model Legislation: Questions and Answers

    These questions and answers explain the role pharmacy benefit managers (PBM) play in the drug supply chain and highlight NASHP’s model PBM legislation that states can use to better oversee PBMs and protect consumers. What are pharmacy benefit managers? Pharmacy benefit managers (PBMs) contract with health plans to administer their pharmacy benefits. Depending what a health […]

    Read More
  • State Health Policy Blog
    Twenty-Eight States Passed 45 Bills to Curb Rising Rx Drug Costs in the Short 2018 Legislative Session

    Twenty-Eight States Passed 45 Bills to Curb Rising Rx Drug Costs in the Short 2018 Legislative Session

    *Updated Oct. 15, 2018 Despite a short legislative season, state lawmakers across the country introduced an unprecedented 174 bills to stem the rising cost of prescription drugs and have enacted 45 into law — with seven state legislatures still in session. Last year, state legislatures introduced 100 Rx cost control bills and passed 27. Register […]

    Read More
  • Feds Send Mixed Responses on States’ Efforts to Control Medicaid Drug Costs

    Feds Send Mixed Responses on States’ Efforts to Control Medicaid Drug Costs

    The Centers for Medicare & Medicaid Services (CMS) had a mixed response to two states’ innovative efforts to control Medicaid drug costs in June. The agency denied Massachusetts’ 1115 waiver request to create a closed Medicaid drug formulary, but it approved Oklahoma’s State Plan Amendment that authorizes supplemental rebates for value-based purchasing arrangements with pharmaceutical […]

    Read More
    July 10, 2018 | Filed under: All, Drug Pricing, Featured-Rx, Front Page, Front Page-Rx, Medicaid

  • State Health Policy Blog
    The Federal Government Considers Updating Data Collection and Analysis of Drug Prices

    The Federal Government Considers Updating Data Collection and Analysis of Drug Prices

    The Trump Administration announced a series of initiatives earlier this month to reduce prescription drug prices and patient drug costs. Its American Patients First provides an outline of ideas for future action and reprises initiatives the Administration recently began. The Administration is now seeking public input on many of these proposed policies. The Administration’s Request […]

    Read More
  • State Health Policy Blog
    How Vermont Will Implement Its Groundbreaking Rx Drug Importation Law

    How Vermont Will Implement Its Groundbreaking Rx Drug Importation Law

    Vermont is the first state in the nation to approve a wholesale program to import lower-cost prescription drugs from Canada, following Gov. Phil Scott’s signing of the landmark law last week. Vermont now begins the task of winning approval from the secretary of the US Department of Health and Human Services (HHS) and implementing its […]

    Read More